Literature DB >> 12895200

A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy.

Ferdinando C Sasso, Ornella Carbonara, Pierpaolo Di Micco, Leonardo Coppola, Roberto Torella, Alferio Niglio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895200      PMCID: PMC1884279          DOI: 10.1046/j.0306-5251.2003.01854.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?

Authors:  E Bosi; R Minelli; E Bazzigaluppi; M Salvi
Journal:  Diabet Med       Date:  2001-04       Impact factor: 4.359

Review 2.  The treatment of chronic viral hepatitis.

Authors:  J H Hoofnagle; A M di Bisceglie
Journal:  N Engl J Med       Date:  1997-01-30       Impact factor: 91.245

3.  Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa.

Authors:  M Lisker-Melman; A M Di Bisceglie; S J Usala; B Weintraub; L M Murray; J H Hoofnagle
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  Reversible hypopituitarism after interferonalfa therapy.

Authors:  N Sakane; T Yoshida; K Yoshioka; T Umekawa; M Kondo; A Shimatsu
Journal:  Lancet       Date:  1995-05-20       Impact factor: 79.321

5.  Occurrence of IDDM during interferon therapy for chronic viral hepatitis.

Authors:  M Waguri; T Hanafusa; N Itoh; A Imagawa; J Miyagawa; S Kawata; N Kono; M Kuwajima; Y Matsuzawa
Journal:  Diabetes Res Clin Pract       Date:  1994-02       Impact factor: 5.602

  5 in total
  1 in total

1.  Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.